Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Sante Ventures
AddedFeb 15, 2024
UpdatedJun 28, 2026
Sante Ventures

Sante Ventures

Operating

Sante Ventures: A US-based venture capital firm investing in life sciences, medical tech, and healthcare.

Location
Austin, TX, US
Founded
2006
Firm
Compare
Portfolio
Employees

Investments

Endovascular Engineering
Endovascular Engineering

Total Raised

$137M

Rounds

3

Series C$80MApril 2026
Series B$42MFebruary 2025
Series A$15MApril 2022
Solu Therapeutics
Solu Therapeutics

Total Raised

$31M

Rounds

1

Seed$31MAugust 2023
BeeKeeperAI
BeeKeeperAI

Total Raised

$12.1M

Rounds

1

Series A$12.1MJune 2023
Wave
Wave

Total Raised

$10M

Rounds

3

Seed$6MMarch 2023
Sensorium Therapeutics
Sensorium Therapeutics

Total Raised

$30M

Rounds

1

Series A$30MOctober 2022
Rapidpulse
Rapidpulse

Total Raised

$25.6M

Rounds

2

Series A$10.6MAugust 2022
Series A$15MJune 2021
Geneos Therapeutics
Geneos Therapeutics

Total Raised

$49.5M

Rounds

5

Series A$17MMarch 2022
Series A$12MMarch 2021
Series A$10.5MFebruary 2019
Access Optics
Access Optics

Total Raised

$4.5M

Rounds

1

Series A$4.5MOctober 2021
Cryosa
Cryosa

Total Raised

$29.8M

Rounds

4

Series B$21.5MSeptember 2021
Series A$8.3MJune 2020
Iterion Therapeutics
Iterion Therapeutics

Total Raised

$21.4M

Rounds

5

Series B$17MFebruary 2021
Series B$2.6MJune 2018
Nirogy Therapeutics
Nirogy Therapeutics

Total Raised

$18.5M

Rounds

2

Series A$16.5MJanuary 2021
kelaHealth
kelaHealth

Total Raised

$15.5M

Rounds

6

Seed$2.9MOctober 2020
Series A$10MOctober 2020
Libra Therapeutics
Libra Therapeutics

Total Raised

$29M

Rounds

1

Series A$29MSeptember 2020
Glyscend
Glyscend

Total Raised

$22.4M

Rounds

5

Series A$20.5MJune 2020
BioStable Science & Engineering
BioStable Science & Engineering

Total Raised

$10.8M

Rounds

4

Series CFebruary 2020
Remedy
Remedy

Total Raised

$12.5M

Rounds

4

Series A$10MJune 2019
Endogenex
Endogenex

Total Raised

$25M

Rounds

5

Series ANovember 2018